The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer.
Heather H. Cheng
No relevant relationships to disclose
Hongli Li
No relevant relationships to disclose
Celestia S. Higano
Research Funding - ImClone Systems
Catherine M. Tangen
No relevant relationships to disclose
Neeraj Agarwal
Consultant or Advisory Role - Exelixis (U); Medivation (U)
Honoraria - Dendreon
Research Funding - Amgen; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; ImClone Systems; Medivation; Novartis; Pfizer; Takeda
James Yan
No relevant relationships to disclose
Nicholas J. Vogelzang
Consultant or Advisory Role - Veridex
Honoraria - Veridex
Maha Hussain
Research Funding - ImClone Systems
Ian Murchie Thompson
No relevant relationships to disclose
Muneesh Tewari
No relevant relationships to disclose
Evan Y. Yu
Research Funding - ImClone Systems; Veridex